Abstract:AMPK activation appears in a healthy liver during fasting in response to energy generation needs. AMPK enhances FA oxidation and autophagy, reducing lipid accumulation. mTORC1 activation occurs in high food intake in a diseased liver, leading to lipogenesis, reducing FA oxidation, lipolysis, and autophagy, leading to liver lipid accumulation and NAFLD. ACC2, acetyl‐Coa carboxylase 2; AKT, protein kinase B; AMPK, AMP‐activated protein kinase; CPT1, carnitine palmitoyl transferase I; DNL, de novo lipogenesis; FA, fatty acid; GTP, GTPase‐activating protein; HSL, hormone‐sensitive lipase; IR, insulin receptor; LKB, liver kinase B; mTOR, mechanistic target of rapamycin; NAFLD, non‐alcoholic fatty liver disease; PGC‐1α, peroxisome proliferator‐activated receptor‐gamma coactivator‐1 alpha; PI3K, phosphoinositide 3‐ kinase; PPARa, peroxisome proliferator‐activated receptors alpha; RHEB, Ras homolog enriched in the brain; TSC, tuberous sclerosis complex; ULK1, unc‐51‐like kinase 1. Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.

Hepatic autophagy fluctuates during the development of non-alcoholic fatty liver disease

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

Dysfunction of Autophagy in High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease

Sa1666 IGFBP1 Decreases Free Fatty Acid-Induced Hepatocyte Steatosis through Phosphorylation of FAK

Sa1668 Proteomic Analysis of Nonalcoholic Fatty Liver Disease: Attenuation of Coactosin-like Protein-1 Protects Liver from Steatosis and Injury

Sa1667 Hepatic-Specific Activation of Peroxisome Proliferator-Activated Receptor Y Coactivator-1α Protected Against Steatohepatitis

Glucose Fluctuation Increased Hepatocyte Apoptosis under Lipotoxicity and the Involvement of Mitochondrial Permeability Transition Opening.

The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease

Impaired Mitophagy Triggers NLRP3 Inflammasome Activation During the Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Mechanisms and therapeutic implications of selective autophagy in nonalcoholic fatty liver disease

AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression

Osteopontin Acts As a Negative Regulator of Autophagy Accelerating Lipid Accumulation During the Development of Nonalcoholic Fatty Liver Disease

Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease

Palmitic Acid Induces Autophagy in Hepatocytes Via JNK2 Activation.

Autophagy Induced by Palmitic Acid: a Brake in NAFLD Neutrophils

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis

Hepatic CD147 Knockout Modulates Liver Steatosis and Up-Regulates Autophagy in High-Fat-diet-induced NAFLD Mice.

Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy

Mitophagy regulation after diet and exercise in non‐alcoholic fatty liver disease

ALCAT1 Controls Mitochondrial Etiology of Fatty Liver Diseases, Linking Defective Mitophagy to Steatosis.

Activation of Mtorc1 Disrupted LDL Receptor Pathway: a Potential New Mechanism for the Progression of Non-Alcoholic Fatty Liver Disease.